MC2 Therapeutics is a privately held emerging dermatology and eye care pharmaceutical company.
Using our proprietary PAD™ Technology – a new class of vehicle – we are developing a pipeline of new topical drugs with superior real-life clinical profiles designed for optimal patient compliance. We aim to provide a unique experience for patients and an attractive benefit to value proposition for payers.
Many topical diseases are chronic and require life-long treatment. We believe that such therapies shall not only provide (i) rapid relief of symptoms, but also (ii) maintain long-term remission and (iii) be simple, pleasant and safe to use without disturbing daily routines. Our patient centric approach is fueled by combining the most efficacious and safe API’s with our elegant PAD™ vehicles – making new drugs that sets a new standard and enables a paradigm shift. One product for both rapid relief and maintenance therapy so elegant and tolerable that patient will want to use it everyday.
We are satisfied when patients using PAD™ based drugs feel free to engage with other people and be as active and social as they want during treatment.